Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND”, ranging from target validation and antibody discovery through preclinical research, has partnered with Kodiak Sciences Inc. to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona’s proprietary Harbour Mice fully human antibody platform.
 
The Harbour Mice platform produces fully human monoclonal antibodies in both H2L2 (two heavy and two light chains) and HCAb (heavy chain-only) formats, removing the necessity for further engineering or humanization. Notably, the HCAb Harbour Mice platform is revolutionizing antibody development by generating unique, fully human heavy chain-only antibodies that are roughly half the size of standard IgGs, which presents considerable benefits for next-generation antibody therapies. As per the agreement, Kodiak Sciences has the right to utilize both the H2L2 and HCAb Harbour Mice platforms across several programs for therapeutic antibody discovery and development.
 
“We are pleased to collaborate with Kodiak Sciences to advance novel antibody therapies for ophthalmic diseases,” said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. “This agreement further validates our proprietary Harbour Mice technology platform. With Nona’s industry-leading technology and expertise, we look forward to supporting Kodiak Sciences in accelerating their next-generation therapeutic antibody development and bringing more innovative therapies to patients.”
 
“Retinal diseases involve a complex etiology, so advancing more effective therapies will require targeting multiple pathways at once,” said Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences Inc. “We are thrilled to announce our partnership with Nona Biosciences, leveraging their advanced Harbour Mice platforms and robust expertise in antibody discovery. This collaboration will accelerate our mission to create next generation biotherapeutics, combining our strengths to bring innovative treatments to patients in need.”

Related News